Rick Doblin is the founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501c3 nonprofit organization dedicated to developing psychedelics and marijuana into prescription medicines. Currently MAPS is preparing for FDA-approved Phase 3 Clinical Trials examining the safety and efficacy of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), these are the final round of studies before requesting approval as a FDA-approved treatment, which is anticipated for 2021.

In today's show, we hope discuss a wide range of topics in the field of psychedelic medicine, including: